G1 Therapeutics, Inc.·4

Mar 17, 4:20 PM ET

Umstead John V. 4

4 · G1 Therapeutics, Inc. · Filed Mar 17, 2023

Insider Transaction Report

Form 4
Period: 2023-03-15
Umstead John V.
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2023-03-15+50,00058,886 total
  • Award

    Stock Options (Right to Buy)

    2023-03-15+100,000100,000 total
    Exercise: $3.27Exp: 2033-03-15Common Stock (100,000 underlying)
Footnotes (4)
  • [F1]Represents a restricted stock unit ("RSU") award that vests 25% on March 15, 2024 and 25% annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
  • [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
  • [F3]Represents (i) 2,036 shares of common stock; (ii) 850 RSUs from award granted on January 4, 2021; (iii) 3,000 RSUs from award granted on January 3, 2022; (iv) 3,000 RSUs from award granted on January 3, 2023; and (v) 50,000 RSUs from award granted on March 15, 2023.
  • [F4]The shares underlying this option vest as to 25% of the shares on March 15, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Documents

2 files
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT

  • EX-24

    POWER OF ATTORNEY